АГ. JournalofHypertension
 Скачать 1.94 Mb.
|
|
Литература 1. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21:1011–1053. 2. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25:1105–1187. 3. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a metaanalysis of individual datafor one million adults in 61 prospective studies. Lancet 2002; 360:1903–1913. 4. Britton KA, Gaziano JM, Djousse L. Normal systolic blood pressure and risk of heart failure in US male physicians. Eur J Heart Fail 2009; 11:1129–1134. 5. Kalaitzidis RG, Bakris GL. Prehypertension: is it relevant for nephrologists? Kidney Int 2010; 77:194–200. 6. Asia Pacific Cohort Studies Collaboration. Blood pressure and cardiovascular disease in the Asia Pacific region. J Hypertens 2003; 21:707–716. 7. Brown DW, Giles WH, Greenlund KJ. Blood pressure parameters and risk of fatal stroke, NHANES II mortality study. Am J Hypertens 2007; 20:338–341. 8. Franklin SS, Gustin WIV, Wong ND, Larson MG, Weber MA, Kannel WB, Levy D. Haemodynamic patterns of age-related changes in blood pressure. The Framingham Heart Study. Circulation 1997; 96:308–315. 9. Vishram JK, Borglykke A, Andreasen AH, Jeppesen J, Ibsen H, J0rgensen T, et al., on behalf of the MORGAM Project. Impact of Age on the Importance of Systolic and Diastolic Blood Pressures for Stroke Risk: The MOnica, Risk, Genetics, Archiving and Monograph (MORGAM) Project. Hypertension 2012; 60:1117–1123. 10. Benetos A, Safar M, Rudnichi A, Smulyan H, Richard JL, Ducimetieere P, Guize L. Pulse pressure: a predictor of long-term cardiovascular mortality in a French male population. Hypertension 1997; 30:1410–1415. 11. Kannel WB, Wolf PA, McGee DL, Dawber TR, McNamara P, Castelli WP. Systolic blood pressure arterial rigidity risk of stroke. The Framingham study. JAMA 1981; 245:1225–1229. 12. Kannel WB. Risk stratification in hypertension: new insights from the Framingham Study. Am J Hypertens 2000; 13:3S–10S. 13. Thomas F, Rudnichi A, Bacri AM, Bean K, Guize L, Benetos A. Cardiovascular mortality in hypertensive men according to presence of associated risk factors. Hypertension 2001; 37:1256–1261. 14. Pickering G. Hypertension. Definitions, natural histories and consequences. Am J Med 1972; 52:570–583. 15. Lurbe E, Cifkova R, Cruickshank JK, Dillon MJ, Ferreira I, Invitti C, et al. Management of high blood pressure in children and adolescents: recommendations of the European Society of Hypertension. J Hypertens 2009; 27:1719–1742. 16. Pereira M, Lunet N, Azevedo A, Barros H. Differences in prevalence, awareness, treatment and control of hypertension between developing and developed countries. J Hypertens 2009; 27:963–975. 17. Danon-Hersch N, Marques-Vidal P, Bovet P, Chiolero A, Paccaud F, Pecoud A, et al. Prevalence, awareness, treatment and control of high blood pressure in a Swiss city general population: the Co Laus study. Eur J Cardiovasc Prev Rehabil 2009; 16:66–72. 18. Altun B, Arici M, Nergizoglu G, Derici U, Karatan O, Turgan C, et al. Prevalence, awareness, treatment and control of hypertension in Turkey (the PatenT study) in 2003. J Hypertens 2005; 23:1817–1823. 19. Tugay Aytekin N, Pala K, Irgil E, Akis N, Aytekin H. Distribution of blood pressures in Gemlik District, north-west Turkey. Health Soc Care Community 2002; 10:394–401. 20. Efstratopoulos AD, Voyaki SM, Baltas AA, Vratsistas FA, Kirlas DE, Kontoyannis JT, et al. Prevalence, awareness, treatment and control of hypertension in Hellas, Greece: the Hypertension Study in General Practice in Hellas (HYPERTENSHELL) national study. Am J Hypertens 2006; 19:53–60. 21. Macedo ME, Lima MJ, Silva AO, Alcantara P, Ramalhinho V, Carmona J. Prevalence, awareness, treatment and control of hypertension in Portugal: the PAP study. J Hypertens 2005; 23:1661–1666. 22. Psaltopoulou T, Orfanos P, Naska A, Lenas D, Trichopoulos D, Trichopoulou A. Prevalence, awareness, treatment and control of hypertension in a general population sample of adults in the Greek EPIC study. Int J Epidemiol 2004; 33:1345–1352. 23. Sarafidis PA, Lasaridis A, Gousopoulos S, Zebekakis P, Nikolaidis P, Tziolas I, Papoulidou F. Prevalence, awareness, treatment and control of hypertension in employees of factories of Northern Greece: the Naoussa study. J Hum Hypertens 2004; 18:623–629. 24. Panagiotakos DB, Pitsavos CH, Chrysohoou C, Skoumas J, Papadimitriou L, Stefanadis C, Toutouzas PK. Status and management of hypertension in Greece: role of the adoption of a Mediterranean diet: the Attica study. J Hypertens 2003; 21:1483–1489. 25. Banegas JR, Graciani A, de la Cruz-Troca JJ, Leon-Munoz LM, Guallar-Castillon P, Coca A, et al. Achievement of cardiometabolic targets in aware hypertensive patients in Spain: a nationwide population-based study. Hypertension 2012; 60:898–905. 26. Primatesta P, Poulter NR. Improvement in hypertension management in England: results from the Health Survey for England 2003. J Hypertens 2006; 24:1187–1192. 27. Meisinger C, Heier M, Volzke H, Lowel H, Mitusch R, Hense HW, Ludemann J. Regional disparities of hypertension prevalence and management within Germany. J Hypertens 2006; 24:293–299. 28. Agyemang C, Ujcic-Voortman J, Uitenbroek D, Foets M, Droomers M. Prevalence and management of hypertension among Turkish, Moroccan and native Dutch ethnic groups in Amsterdam, the Netherlands: The Amsterdam Health Monitor Survey. J Hypertens 2006; 24:2169–2176. 29. Agyemang C, Bindraban N, Mairuhu G, Montfrans G, Koopmans R, Stronks K. Prevalence, awareness, treatment and controlofhypertension among Black Surinamese, South Asian Surinamese and White Dutch in Amsterdam, The Netherlands: the SUNSET study. J Hypertens 2005; 23:1971–1977. 30. Scheltens T, Bots ML, Numans ME, Grobbee DE, Hoes AW. Awareness, treatment and control of hypertension: the ‘rule of halves’ in an era of risk-based treatment of hypertension. J Hum Hypertens 2007; 21:99–106. 31. Zdrojewski T, Szpakowski P, Bandosz P, Pajak A, Wiecek A, Krupa-Wojciechowska B, Wyrzykowski B. Arterial hypertension in Poland in 2002. J Hum Hypertens 2004; 18:557–562. 32. Cifkova R, Skodova Z, Lanska V, Adamkova V, Novozamska E, Jozifova M, et al. Prevalence, awareness, treatment and control of hypertension in the Czech Republic. Results of two nationwide cross sectional surveys in 1997/1998 and 2000/2001, Czech Post-MONICA Study. J Hum Hypertens 2004; 18:571–579. 33. Scuteri A, Najjar SS, Orru M, Albai G, Strait J, Tarasov KV, et al. Ageand gender-specific awareness, treatment and control of cardiovascular risk factors and subclinical vascular lesions in a founder population: the Sardinia Study. Nutr Metab Cardiovasc Dis 2009; 19:532–541. 34. Kastarinen M, Antikainen R, Peltonen M, Laatikainen T, Barengo NC, Jula A, et al. Prevalence, awareness and treatment of hypertension in Finland during 1982–2007. J Hypertens 2009; 27:1552–1559. 35. Falaschetti E, Chaudhury M, Mindell J, Poulter N. Continued improvement in hypertension management in England: results from the Health Survey for England 2006. Hypertension 2009; 53:480–486. 36. Erem C, Hacihasanoglu A, Kocak M, Deger O, Topbas M. Prevalence of prehypertension and hypertension and associated risk factors among Turkish adults: Trabzon Hypertension Study. J Public Health (Oxf) 2009; 31:47–58. 37. Costanzo S, Di Castelnuovo A, Zito F, Krogh V, Siani A, Arnout J, et al. Prevalence, awareness, treatment and control of hypertension in healthy unrelated male-female pairs of European regions: the dietary habit profile in European communities with different risk of myocardial infarction: the impact of migration as a model of geneenvironment interaction project. J Hypertens 2008; 26:2303–2311. 38. Cooper RS. Using public health indicators to measure the success of hypertension control. Hypertension 2007; 49:773–774. 39. Wolf-Maier K, Cooper RS, Banegas JR, Giampaoli S, Hense HW, Joffres M, et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada and the United States. JAMA 2003; 289:2363–2369. 40. Redon J, Olsen MH, Cooper RS, Zurriaga O, Martinez-Beneito MA, Laurent S, et al. Stroke mortality trends from 1990 to 2006 in 39 countries from Europe and Central Asia: implications for control of high blood pressure. Eur Heart J 2011; 32:1424–1431. 41. Pyorala K, De Backer G, Graham I, Poole-Wilson P, Wood D. Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Eur Heart J 1994; 15:1300–1331. 42. D’Agostino RB Sr, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, Kannel WB. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 2008; 117:743–753. 43. Conroy RM, Pyorala K, Fitzgerald AP, Sans S, Menotti A, De Backer G, et al. Estimation often-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003; 24:987–1003. 44. Woodward M, Brindle P, Tunstall-Pedoe H. Adding social deprivation and family history to cardiovascular risk assessment: the ASSIGN score from the Scottish Heart Health Extended Cohort (SHHEC). Heart 2007; 93:172–176. 45. Hippisley-Cox J, Coupland C, Vinogradova Y, Robson J, Minhas R, Sheikh A, Brindle P. Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2. BMJ 2008;336:1475–1482. 46. Assmann G, Cullen P, Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Munster (PROCAM) study. Circulation 2002; 105:310–315. 47. Ridker PM, Paynter NP, Rifai N, Gaziano JM, Cook NR. C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds Risk Score for men. Circulation 2008; 118:2243–2251; 2244p following 2251. 48. Ridker PM, Buring JE, Rifai N, Cook NR. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA 2007;297:611–619. 49. Cooney MT, Dudina AL, Graham IM. Value and limitations of existing scores for the assessment of cardiovascular risk: a review for physicians. J Am Coll Cardiol 2009; 54:1209–1227. 50. Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 2012; 33:1635–1701. 51. Sehestedt T, Jeppesen J, Hansen TW, Wachtell K, Ibsen H, Torp-Pedersen C, et al. Risk prediction is improved by adding markers of subclinical organ damage to SCORE. Eur Heart J 2010; 31:883–891. 52. Sehestedt T, Jeppesen J, Hansen TW, Rasmussen S, Wachtell K, Ibsen H, et al. Thresholds for pulse wave velocity, urine albumin creatinine ratio and left ventricular mass index using SCORE, Framingham and ESH/ESC risk charts. J Hypertens 2012; 30:1928–1936. 53. Volpe M, Battistoni A, Tocci G, Agabiti Rosei E, Catapano AL, Coppo R, et al. Cardiovascular risk assessment beyond systemic coronary risk estimation: a role for organ damage markers. J Hypertens 2012; 30:1056–1064. 54. Guidelines Sub committee 1999. World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. J Hypertens 1999; 17:151–183. 55. World Health Organization, International Society of Hypertension Writing Group. World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003; 21:1983–1992. 56. O’Brien E, Waeber B, Parati G, Staessen J, Myers MG. Blood pressure measuring devices: recommendations of the European Society of Hypertension. BMJ 2001; 322:531–536. 57. Clark CE, Taylor RS, Shore AC, Ukoumunne OC, Compbell JL. Association of a difference in systolic blood pressure between arms with vascular disease and mortality: a systematic review and metaanalysis. Lancet 2012; 379:905–914. 58. Fedorowski A, Stavenow L, Hedblad B, Berglund G, Nilsson PM, Melander O. Orthostatic hypotension predicts all-cause mortality and coronary events in middle-aged individuals (The Malmo Preventive Project). Eur Heart J 2010; 31:85–91. 59. Fagard RH, De Cort P. Orthostatic hypotension is a more robust predictor of cardiovascular events than night-time reverse dipping in elderly. Hypertension 2010; 56:56–61. 60. Trazzi S, Mutti E, Frattola A, Imholz B, Parati G, Mancia G. Reproducibility of noninvasive and intra-arterial blood pressure monitoring: implications for studies on antihypertensive treatment. J Hypertens 1991; 9:115–119. 61. Myers MG, Godwin M, Dawes M, Kiss A, Tobe SW, Kaczorowski J. Measurement of blood pressure in the office: recognizing the problem and proposing the solution. Hypertension 2010; 55:195–200. 62. Julius S, Palatini P, Kjeldsen SE, Zanchetti A, Weber MA, McInnes GT, et al. Usefulness of heart rate to predict cardiac events in treated patients with high-risk systemic hypertension. Am J Cardiol 2012;109:685–692. 63. Benetos A, Rudnichi A, Thomas F, Safar M, Guize L. Influence of heart rate on mortality in a French population: role of age, gender and blood pressure. Hypertension 1999; 33:44–52. 64. O’Brien E, Asmar R, Beilin L, Imai Y, Mancia G, Mengden T, et al. Practice guidelines of the European Society of Hypertension for clinic, ambulatory and self blood pressure measurement. J Hypertens 2005; 23:697–701. 65. O’Brien E, Parati G, Stergiou G, Asmar R, Beilin L, Bilo G, et al., on behalf of the European Society of Hypertension Working Group on Blood Pressure Monitoring. European Society of Hypertension position paper on ambulatory blood pressure monitoring. J Hypertens 2013; in press. 66. Parati G, Stergiou GS, Asmar R, Bilo G, de Leeuw P, Imai Y, et al. European Society of Hypertension practice guidelines for home blood pressure monitoring. J Hum Hypertens 2010; 24:779–785. 67. Parati G, Stergiou GS, Asmar R, Bilo G, de Leeuw P, Imai Y, et al., European Societyof Hypertension Working Groupon Blood Pressure Monitoring. European Society of Hypertension guidelines for blood pressure monitoring at home: a summary report of the Second International Consensus Conference on Home Blood Pressure Monitoring. J Hypertens 2008; 26:1505–1526. 68. Mancia G, Omboni S, Parati G, Trazzi S, Mutti E. Limited reproducibility of hourly blood pressure values obtained by ambulatory blood pressure monitoring: implications for studies on antihypertensive drugs. J Hypertens 1992; 10:1531–1535. 69. Di Rienzo M, Grassi G, Pedotti A, Mancia G. Continuous vs intermittent blood pressure measurements in estimating 24-h average blood pressure. Hypertension 1983; 5:264–269. 70. Stergiou GS, Kollias A, Destounis A, Tzamouranis D. Automated blood pressure measurement in atrial fibrillation: a systematic review and meta-analysis. J Hypertens 2012; 30:2074–2082. 71. Fagard R, Brguljan J, Thijs L, Staessen J. Prediction of the actual awake and asleep blood pressures by various methods of 24 h pressure analysis. J Hypertens 1996; 14:557–563. 72. Octavio JA, Contreras J, Amair P, Octavio B, Fabiano D, Moleiro F, et al. Time-weighted vs. conventional quantification of 24-h average systolic and diastolic ambulatory blood pressures. J Hypertens 2010; 28:459–464. 73. Omboni S, Parati G, Palatini P, Vanasia A, Muiesan ML, Cuspidi C, Mancia G. Reproducibility and clinical value of nocturnal hypotension: prospective evidence from the SAMPLE study. Study on Ambulatory Monitoring of Pressure and Lisinopril Evaluation. J Hypertens 1998; 16:733–738. 74. Stenehjem AE, Os I. Reproducibility of blood pressure variability, white-coat effect and dipping pattern in untreated, uncomplicated and newly diagnosed essential hypertension. Blood Press 2004; 13:214–224. 75. Mancia G. Short- and long-term blood pressure variability: present and future. Hypertension 2012; 60:512–517. 76. Kario K, Pickering TG, Umeda Y, Hoshide S, Hoshide Y, Morinari M, et al. Morning surge in blood pressure as a predictor of silent and clinical cerebrovascular disease in elderly hypertensives: a prospective study. Circulation 2003; 107:1401–1406. 77. Head GA, Chatzivlastou K, Lukoshkova EV, Jennings GL, Reid CM. A novel measure of the power of the morning blood pressure surge from ambulatory blood pressure recordings. Am J Hypertens 2010; 23:1074–1081. 78. White WB. Blood pressure load and target organ effects in patients with essential hypertension. J Hypertens 1991; 9 (Suppl 8):S39–S41. 79. Li Y, Wang JG, Dolan E, Gao PJ, Guo HF, Nawrot T, et al. Ambulatory arterial stiffness index derived from 24-h ambulatory blood pressure monitoring. Hypertension 2006; 47:359–364. 80. Parati G, Schillaci G. What are the real determinants of the ambulatory arterial stiffness index? J Hypertens 2012; 30:472–476. 81. Verdecchia P, Angeli F, Mazzotta G, Garofoli M, Ramundo E, Gentile G, et al. Day-night dip and early-morning surge in blood pressure in hypertension: prognostic implications. Hypertension 2012; 60:34–42. |